Control group:Irinotecan

3 trials

Sponsors

Zhujiang Hospital of Southern Medical University, The First People's Hospital of Yancheng City, Jiangsu Province, Shanghai Pulmonary Hospital

Conditions

Advanced esophageal squamous cell cancerLung cancersmall cell lung cancer

Phase 2

Efficacy and safety of irinotecan combined with retitroxel regimen in salvage chemotherapy for advanced esophageal squamous cell carcinoma

RecruitingChiCTR1900027159

The First People's Hospital of Yancheng City, Jiangsu ProvinceAdvanced esophageal squamous cell cancer

Start: 2019-11-01Updated: 2019-11-04

Phase 4

Pd-1 monoclonal antibody SHR-1210 combined with irinotecan versus irinotecan for the second-line treatment of extensive small-cell lung cancer in a multicenter, randomized, controlled clinical study

Active, not recruitingChiCTR1900027139

Zhujiang Hospital of Southern Medical UniversityLung cancer

Start: 2019-12-01Updated: 2019-11-04

Pembrolizumab Plus Irinotecan vs Irinotecan in Patients With Refractory Small-cell Lung Cancer

RecruitingChiCTR2000037396

Shanghai Pulmonary Hospitalsmall cell lung cancer

Start: 2020-10-01Updated: 2020-10-19